Goldfinch Bio, a 2020 Fierce Biotech Fierce 15 winner, is shutting down. CEO Tony Johnson and Chief Financial and Operating Officer Kyle Kuvalanka told Fierce Biotech that the company is closing ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a biotechnology company focused on discovering and developing precision medicines for the treatment of genetically-driven kidney diseases ...

Goldfinch Bio’s kidney disease treatment quelled rising protein levels in patients’ urine, but only in one of the two diseases being tested, according to initial data from a phase 2 trial.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Goldfinch Bio, a biotechnology company focused on discovering and developing precision medicines for the treatment of genetically-driven kidney diseases ...

Please provide your email address to receive an email when new articles are posted on . Biopharmaceutical company Karuna Therapeutics has announced an exclusive license agreement with biotech firm ...

Gilead Sciences will partner with Goldfinch Bio to discover, develop, and commercialize new therapeutics for diabetic kidney disease (DKD) and orphan kidney diseases, the companies said today ...

CAMBRIDGE, Mass. and ANN ARBOR, Mich., Oct. 3, 2017 /PRNewswire/ -- Goldfinch Bio, a company singularly focused on discovering and developing precision therapies to treat patients with kidney ...

Optibrium and Goldfinch Bio have announced that the company has signed a multi-year agreement to license Optibrium’s StarDrop software. The agreement will see the deployment of six of StarDrop’s ...

GOLDFINCH BIO - FINANCING INCLUDED INVESTORS WELLINGTON MANAGEMENT, FUNDS & ACCOUNTS MANAGED BY BLACKROCK, & GILEAD SCIENCES, YONJIN CAPITAL & OTHERS Source text for Eikon: Further company ...

Goldfinch Bio, a Cambridge biotech startup seeking to develop precision medicines for people with kidney disease, will receive at least $109 million in a business deal with the California ...